Pliant Therapeutics (PLRX) Set to Post Quarterly Earnings on Thursday

Pliant Therapeutics (NASDAQ:PLRX) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Pliant Therapeutics to post earnings of ($0.37) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Pliant Therapeutics (NASDAQ:PLRX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). On average, analysts expect Pliant Therapeutics to post ($1.42) EPS for the current fiscal year and ($1.53) EPS for the next fiscal year.

Pliant Therapeutics Stock Performance

Shares of PLRX stock opened at $0.84 on Tuesday. Pliant Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $1.81. The firm has a market capitalization of $51.96 million, a price-to-earnings ratio of -0.56 and a beta of 1.27. The stock’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.16.

Analysts Set New Price Targets

Several equities analysts recently commented on PLRX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pliant Therapeutics presently has an average rating of “Hold” and an average price target of $3.00.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver.

Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins ?v?1 and ?v?6.